Table 1.
Demographic and Clinical Characteristics of 70 Patients with CRAB Infection Enrolled in this Study
| ST540 (n = 34) | Non-ST540 (n = 36) | P | |
|---|---|---|---|
| Age (years), mean ± SD | 53.56 ± 21.65 | 59.00 ± 19.48 | 0.48 |
| Male gender | 25 | 17 | 0.02* |
| Comorbid disease | |||
| Pulmonary infection | 16 | 15 | 0.65 |
| Abdominal infection | 6 | 6 | 0.91 |
| Chronic kidney disease | 3 | 5 | 0.51 |
| Chronic liver failure | 4 | 3 | 0.63 |
| Coronary disease | 5 | 2 | 0.20 |
| COPD | 1 | 1 | 0.97 |
| Diabetes mellitus | 7 | 7 | 0.90 |
| Neurological disease | 12 | 10 | 0.50 |
| Cancer | 4 | 4 | 0.93 |
| Organ failure | |||
| Respiratory failure | 19 | 17 | 0.47 |
| Shock | 6 | 10 | 0.24 |
| Laboratory finding | |||
| WBC count, mean ± SD | 9.09 ± 3.82 | 10.79 ± 6.54 | 0.20 |
| PCT, mean ± SD | 4.87 ± 14.19 | 3.33 ± 5.50 | 0.04* |
| CRP level, mean ± SD | 99.65 ± 127.60 | 72.98 ± 65.70 | 0.77 |
| Infectious disease | |||
| HIV | 6 | 3 | 0.24 |
| Syphilis | 0 | 2 | 0.16 |
| Hepatitis B virus | 0 | 1 | 0.33 |
| Epstein-Barr virus infection | 1 | 0 | 0.30 |
| Invasive procedures | |||
| Mechanical ventilation | 20 | 21 | 0.97 |
| Central venous catheter | 22 | 23 | 0.94 |
| Foley catheter | 31 | 32 | 0.75 |
| Use of antibiotics within 30 days prior to bacteremia | |||
| Lactamase Inhibitors | 12 | 17 | 0.31 |
| Carbapenems | 15 | 17 | 0.79 |
| Quinolones | 6 | 9 | 0.38 |
| Cephalosporin | 4 | 2 | 0.35 |
| Aminoglycoside | 3 | 5 | 0.51 |
| Glycopeptide | 6 | 12 | 0.13 |
| Antifungal | 9 | 11 | 0.71 |
| 7-day mortality | 1 | 1 | 0.97 |
| 14-day mortality | 6 | 1 | 0.04* |
| 28-day mortality | 7 | 2 | 0.06 |
Abbreviations: COPD, chronic obstructive pulmonary disease; WBC, white blood cell; PCT, procalcitonin; CRP, C-reactive protein; HIV, human immunodeficiency virus continuous renal replacement therapy; In total, 70 patients were included for the analysis of 7-day, 14-day and 28-day mortality. *P < 0.05: ST540 group vs non-ST540 group (14-day mortality; P = 0.04; pairwise analysis).